Total trials
116
Active
21
Phase 3
24
Total enrollment
13,570
Pipeline matrix
Showing 12 of 12 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Eplontersen | — | — | — | — | 5 | ||
| Olezarsen | — | — | 10 | ||||
| ION582 | — | — | — | — | 2 | ||
| Donidalorsen | — | — | 7 | ||||
| ION363 | — | — | — | — | — | 1 | |
| zilganersen | — | — | — | — | 2 | ||
| ION717 | — | — | — | — | — | 1 | |
| ION337 | — | — | — | — | — | 1 | |
| ION775 | — | — | — | — | — | 1 | |
| ION440 | — | — | — | — | — | 1 | |
| ION356 | — | — | — | — | — | 1 | |
| ION464 | — | — | — | — | — | 1 |
Next readouts
- 2025-08-22
- 2026-04
- 2026-06
- 2026-12
- 2027-02
- 2027-03
- 2027-06
- 2027-08
- 2027-09
- 2027-09
Top conditions
- Type 2 Diabetes Mellitus10
- Hypertriglyceridemia6
- Hereditary Angioedema5
- Healthy Volunteers5
- Severe Hypertriglyceridemia5
- Familial Chylomicronemia Syndrome5
- Healthy Participants4
- Cytomegalovirus Retinitis4
Frequently asked questions about Ionis Pharmaceuticals, Inc.
- How many clinical trials does Ionis Pharmaceuticals, Inc. have on ClinicalTrials.gov?
- Ionis Pharmaceuticals, Inc. is listed as the lead sponsor on 116 clinical trials in ClinicalTrials.gov, 21 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Ionis Pharmaceuticals, Inc.'s trials are in Phase 3?
- 24 of Ionis Pharmaceuticals, Inc.'s trials are in Phase 3, spread across 12 active drug programs.
- What therapeutic areas does Ionis Pharmaceuticals, Inc. focus on?
- Ionis Pharmaceuticals, Inc.'s most-studied conditions on ClinicalTrials.gov are Type 2 Diabetes Mellitus, Hypertriglyceridemia, Hereditary Angioedema, Healthy Volunteers, Severe Hypertriglyceridemia.
- When are Ionis Pharmaceuticals, Inc.'s next clinical trial readouts?
- Ionis Pharmaceuticals, Inc. has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)”, expected around 2025-08-22.